The optimal chemotherapy timing in patients with inoperable locally advanced non small cell lung cancer

Med Arch. 2013;67(2):104-6. doi: 10.5455/medarh.2013.67.104-106.

Abstract

Background: Only 20% of patients with stage III NSCLC are cured by surgery. There is a disagreement among the oncologists in terms of whether which regimen (induction chemotherapy followed chemoradiotherapy, concurrent chemoradiation or concurrent chemoradiation followed consolidation chemotherapy) is best choice in inoperable LA NSCLC.

Objective: To evaluate chemotherapy timing in inoperable LA NSCLC (before, only concomitant or after curative chemotherapy).

Materials and methods: Total of 74 consecutive patient with LA NSCLC which was inoperable due to medical condition or stage from Kayseri Research and Training Hospital were analyzed retrospectively. The patients were divided into three groups according to treatment protocols: Induction chemotherapy followed chemoradiotherapy (Ind. CTàCRT), chemoradiotherapy (CRT) and chemoradiotherapy followed consolidation chemotherapy (CRTàCons. CT).

Results: When evaluating progression free survival (PFS), PFS did not significantly differed among the groups (p=0,078). We found significant difference among groups (p = 0.047) in terms of overall survival. While CRTàCons. CT arm had highest mean and median survival times, Ind. CTàCRT arm had worst OS.

Conclusions: CRTàCons. CT treatment modality seems preferable regimen for treatment of inoperable LA NSCLC.

MeSH terms

  • Aged
  • Antineoplastic Agents / therapeutic use*
  • Antineoplastic Combined Chemotherapy Protocols / classification*
  • Carcinoma, Non-Small-Cell Lung* / drug therapy
  • Carcinoma, Non-Small-Cell Lung* / mortality
  • Carcinoma, Non-Small-Cell Lung* / pathology
  • Disease-Free Survival
  • Female
  • Humans
  • Kaplan-Meier Estimate
  • Lung Neoplasms* / drug therapy
  • Lung Neoplasms* / mortality
  • Lung Neoplasms* / pathology
  • Male
  • Middle Aged
  • Neoplasm Invasiveness
  • Neoplasm Staging
  • Time-to-Treatment
  • Turkey / epidemiology

Substances

  • Antineoplastic Agents